INS and type 2 diabetes mellitus: The insulin sensitizer, pioglitazone, has been demonstrated to improve glycemia in insulin-requiring T2DM patients [12–15]; however use of this agent in this setting is associated with significant increased risk for congestive heart failure in addition to weight gain and edema [15–20].